drugset / Trial / NCT03963102

Duration of Ameluz Application in Acral Actinic Keratoses Response

NCT03963102

Phase 4 Terminated 28 enrolled Royal Cornwall Hospitals Trust
RandomizedParallel-groupSingle-blindTreatment

Summary

A phase IV study of a single topical application of ALA for 3 hours or 4 hours to AK on acral sites (hands, feet, arms and legs), and subsequent measurement of clinical efficacy with corresponding PpIX fluorescence imaging.

Timeline

Start
2019-10-30
Primary completion
2024-03-31
Completion
2024-03-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Aminolevulinic Acid Diagnostic / imaging agent Topical

Indications